gliclazide has been researched along with Vascular Diseases in 3 studies
Gliclazide: An oral sulfonylurea hypoglycemic agent which stimulates insulin secretion.
Vascular Diseases: Pathological processes involving any of the BLOOD VESSELS in the cardiac or peripheral circulation. They include diseases of ARTERIES; VEINS; and rest of the vasculature system in the body.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Severe hypoglycemia was strongly associated with increased risks of a range of adverse clinical outcomes." | 2.75 | Severe hypoglycemia and risks of vascular events and death. ( Billot, L; Chalmers, J; de Galan, BE; Grobbee, DE; Heller, S; Kengne, AP; Li, Q; MacMahon, S; Marre, M; Neal, B; Ninomiya, T; Patel, A; Woodward, M; Zoungas, S, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Ohkuma, T | 1 |
| Harris, K | 1 |
| Cooper, M | 1 |
| Grobbee, DE | 3 |
| Hamet, P | 2 |
| Harrap, S | 1 |
| Mancia, G | 2 |
| Marre, M | 3 |
| Patel, A | 2 |
| Rodgers, A | 1 |
| Williams, B | 2 |
| Woodward, M | 3 |
| Chalmers, J | 3 |
| van Steen, SC | 1 |
| Li, Q | 2 |
| Cooper, ME | 1 |
| Colagiuri, S | 1 |
| DeVries, JH | 1 |
| Zoungas, S | 1 |
| de Galan, BE | 1 |
| Billot, L | 1 |
| Ninomiya, T | 1 |
| Neal, B | 1 |
| MacMahon, S | 1 |
| Kengne, AP | 1 |
| Heller, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| ADVANCE - Action in Diabetes and Vascular Disease: Preterax and Diamicron - MR Controlled Evaluation[NCT00145925] | Phase 3 | 11,140 participants (Actual) | Interventional | 2001-06-30 | Completed | ||
| Effects of Vildagliptin/Metformin Combination on Markers of Atherosclerosis, Thrombosis, and Inflammation in Diabetic Patients With Coronary Artery Disease[NCT01604213] | Phase 4 | 60 participants (Actual) | Interventional | 2012-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 trials available for gliclazide and Vascular Diseases
| Article | Year |
|---|---|
Short-Term Changes in Serum Potassium and the Risk of Subsequent Vascular Events and Mortality: Results from a Randomized Controlled Trial of ACE Inhibitors.
Topics: Angiotensin-Converting Enzyme Inhibitors; Diabetes Mellitus, Type 2; Gliclazide; Humans; Hyperkalemi | 2022 |
Haemoglobin glycation index and risk for diabetes-related complications in the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) trial.
Topics: Aged; Antihypertensive Agents; Diabetes Complications; Diabetes Mellitus, Type 2; Drug Combinations; | 2018 |
Severe hypoglycemia and risks of vascular events and death.
Topics: Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Glicla | 2010 |
Severe hypoglycemia and risks of vascular events and death.
Topics: Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Glicla | 2010 |
Severe hypoglycemia and risks of vascular events and death.
Topics: Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Glicla | 2010 |
Severe hypoglycemia and risks of vascular events and death.
Topics: Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Glicla | 2010 |